EBP50 inhibits pancreatic cancer cell growth and invasion by targeting the β‑catenin/E‑cadherin pathway

Ji,Mengyao; Fan,Dikun; Yuan,Lei; Zhang,Yunting; Dong,Weiguo; Peng,Xiulan

doi:10.3892/etm.2015.2684

EBP50 inhibits pancreatic cancer cell growth and invasion by targeting the β‑catenin/E‑cadherin pathway

Authors:
- Mengyao Ji
- Dikun Fan
- Lei Yuan
- Yunting Zhang
- Weiguo Dong
- Xiulan Peng
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Cardiac Surgery, Center Hospital of Nayang, Henan 473009, P.R. China, Department of Information Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China
Published online on: August 14, 2015 https://doi.org/10.3892/etm.2015.2684
Pages: 1311-1316
Copyright: © Ji et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ezrin‑radixin‑moesin (ERM)‑binding phosphoprotein 50 (EBP50) has previously been demonstrated to be associated with the malignant transformation of numerous types of human cancer. The aim of the present study was to investigate the effect of EBP50 overexpression on pancreatic cancer and the underlying mechanism. Reverse transcription‑quantitative polymerase chain reaction was used to detect the expression of EBP50 in human pancreatic cancer tissue specimens. Furthermore, pBK‑CMV‑HA‑EBP50 and the pBK‑CMV‑HA vectors were transfected into pancreatic cancer cells and the effect of EBP50 upregulation on the proliferation and invasion of the cells was investigated. In addition, the effect of EBP50 overexpression on β‑catenin and E‑cadherin expression was evaluated. The results revealed that overexpression of EBP50 suppressed cell growth and invasion in two human pancreatic cancer cell lines. Overexpression of EBP50 also suppressed β‑catenin expression and increased E‑cadherin expression. Thus, the present study demonstrated that EBP50 inhibits pancreatic cancer cell growth and invasion through targeting the β‑catenin/E‑cadherin pathway. The results suggest that EBP50 may function as a potential tumor suppressor and thus may serve as a potential therapeutic target.

View Figures

View References

1	Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP and Boffetta P: Pancreatic cancer: Overview of descriptive epidemiology. Mol Carcinog. 51:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ashour AA, Gurbuz N, Alpay SN, AbdelAziz AA, Mansour AM, Huo L and Ozpolat B: Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med. 18:2235–2251. 2014. View Article : Google Scholar : PubMed/NCBI
3	Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, et al: Pancreatic cancer risk after treatment for Hodgkin lymphoma. Ann Oncol. 25:2073–2079. 2014. View Article : Google Scholar : PubMed/NCBI
4	Cui J, Jiang W, Wang S, Wang L and Xie K: Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 18:2464–2471. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kyuno D, Yamaguchi H, Ito T, Kono T, Kimura Y, Imamura M, Konno T, Hirata K, Sawada N and Kojima T: Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer. World J Gastroenterol. 20:10813–10824. 2014. View Article : Google Scholar : PubMed/NCBI
6	Bao J, Wang S, Gunther LK, Kitajiri SI, Li C and Sakamoto T: The actin-bundling protein TRIOBP-4 and -5 promotes the motility of pancreatic cancer cells. Cancer Lett. 356:367–373. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wang Z and Ma Q: Beta-catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer. Med Hypotheses. 69:816–820. 2007. View Article : Google Scholar : PubMed/NCBI
8	Voltz JW, Brush M, Sikes S, Steplock D, Weinman EJ and Shenolikar S: Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular targets. J Biol Chem. 282:33879–33887. 2007. View Article : Google Scholar : PubMed/NCBI
9	Fuchs SY, Ougolkov AV, Spiegelman VS and Minamoto T: Oncogenic beta-catenin signaling networks in colorectal cancer. Cell Cycle. 4:1522–1539. 2005. View Article : Google Scholar : PubMed/NCBI
10	Georgescu MM, Morales FC, Molina JR and Hayashi Y: Roles of NHERF1/EBP50 in cancer. Curr Mol Med. 8:459–468. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ji M, Yuan L, Lv X, Dong W and Peng X: EBP50 regulates the apoptosis of pancreatic cancer cells by decreasing the expression levels of Bcl-2. Exp Ther Med. 8:919–924. 2014.PubMed/NCBI
12	Lv XG, Ji MY, Dong WG, Lei XF, Liu M, Guo XF, Wang J and Fang C: EBP50 gene transfection promotes 5-fluorouracil-induced apoptosis in gastric cancer cells through Bax- and Bcl-2-triggered mitochondrial pathways. Mol Med Rep. 5:1220–1226. 2012.PubMed/NCBI
13	Ji MY, Fan DK, Lv XG, Peng XL, Lei XF and Dong WG: The detection of EBP50 expression using quantum dot immunohistochemistry in pancreatic cancer tissue and down-regulated EBP50 effect on PC-2 cells. J Mol Histol. 43:517–526. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H, Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014. View Article : Google Scholar : PubMed/NCBI
15	Sun C, Zheng J, Cheng S, Feng D and He J: EBP50 phosphorylation by Cdc2/Cyclin B kinase affects actin cytoskeleton reorganization and regulates functions of human breast cancer cell line MDA-MB-231. Mol Cells. 36:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
16	Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B, Dell'Aquila ME, et al: NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains. Mol Biol Cell. 23:2028–2040. 2012. View Article : Google Scholar : PubMed/NCBI
17	Georgescu MM, Cote G, Agarwal NK and White CL III: NHERF1/EBP50 controls morphogenesis of 3D colonic glands by stabilizing PTEN and ezrin-radixin-moesin proteins at the apical membrane. Neoplasia. 16:365.e1-e2–374.e1-e2. 2014. View Article : Google Scholar
18	Guo G, Yao G, Zhan G, Hu Y, Yue M, Cheng L, Liu Y, Ye Q, Qing G, Zhang Y and Liu H: N-methylhemeanthidine chloride, a novel Amaryllidaceae alkaloid, inhibits pancreatic cancer cell proliferation via down-regulating AKT activation. Toxicol Appl Pharmacol. 280:475–483. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bellizzi A, Malfettone A, Cardone RA and Mangia A: NHERF1/EBP50 in breast cancer: Clinical perspectives. Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sun GY, Wu JX, Wu JS, Pan YT and Jin R: Caveolin-1, E-cadherin and β-catenin in gastric carcinoma, precancerous tissues and chronic non-atrophic gastritis. Chin J Cancer Res. 24:23–28. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H, Liu TJ, McCrea PD and Georgescu MM: Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function. Oncogene. 26:5290–5299. 2007. View Article : Google Scholar : PubMed/NCBI
22	Cornez I and Taskén K: Spatiotemporal control of cyclic AMP immunomodulation through the PKA-Csk inhibitory pathway is achieved by anchoring to an Ezrin-EBP50-PAG scaffold in effector T cells. FEBS Lett. 584:2681–2688. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lazar CS, Cresson CM, Lauffenburger DA and Gill GN: The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell. 15:5470–5480. 2004. View Article : Google Scholar : PubMed/NCBI